1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives […]readmore
Tags : Axsome Therapeutics
Shots: The P-III MOMENTUM study involves assessing of AXS-07 vs PBO and rizatriptan in 1,594 patients in ratio (2:2:2:1) to treat a single migraine attack of moderate or severe intensity. […]readmore
Shots: The US FDA’s ODD may enable Axsome a seven years of marketing exclusivity in the US, with incentives and reduction in user fees of product required for PDUFA act […]readmore